Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 2.19% is 62% below its 5-year average of 5.81%, near the low end of its 5-year range (2.19%–9.74%).
As of the fiscal period ended Tuesday, June 30, 2026. 20.81% below its 12-month average of 2.76%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.19%.
DEBT TO ASSETS RATIO
2.19%
DEBT TO ASSETS RATIO AVG TTM
2.76%
DEBT TO ASSETS RATIO AVG 3Y
4.56%
DEBT TO ASSETS RATIO AVG 5Y
5.81%
DEBT TO ASSETS RATIO AVG 10Y
4.36%
DEBT TO ASSETS RATIO AVG 15Y
4.20%
DEBT TO ASSETS RATIO AVG 20Y
3.85%
CURRENT VS TTM AVG
-20.81%
CURRENT VS 3Y AVG
-52.13%
CURRENT VS 5Y AVG
-62.37%
CURRENT VS 10Y AVG
-49.83%
CURRENT VS 15Y AVG
-47.99%
CURRENT VS 20Y AVG
-43.27%
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+2327.81%
vs the sector median at left
Niagen Bioscience Inc
Market Cap
$214.24M
Debt to Assets Ratio
2.19%
TTM Avg
2.76%
3Y Avg
4.56%
5Y Avg
5.81%
Market Cap
$214.46M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$215.07M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$216.91M
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$210.98M
Debt to Assets Ratio
0.12%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$210.41M
Debt to Assets Ratio
0.16%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$218.30M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$208.31M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Niagen Bioscience Inc (NAGE) | $214.24M | 2.19% | 2.76% | 4.56% | 5.81% |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | 0.03% | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 0.00% | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | 0.09% | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | 0.12% | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | 0.16% | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | 0.05% | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $209.91M | 0.02% | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | 0.12% | N/A | N/A | N/A |
Debt/Assets
2.2%
Debt/Equity
0.03
Current Ratio
6.50
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 2.19% |
| 2026-03-31 | 2.25% |
| 2025-12-31 | 2.65% |
| 2025-09-30 | 3.11% |
| 2025-06-30 | 3.60% |
| 2025-03-31 | 4.33% |
| 2024-12-31 | 3.88% |
| 2024-09-30 | 5.12% |
| 2024-06-30 | 5.78% |
| 2024-03-31 | 5.97% |
| 2023-12-31 | 5.96% |
| 2023-09-30 | 7.08% |
| 2023-06-30 | 7.41% |
| 2023-03-31 | 7.60% |
| 2022-12-31 | 7.88% |
| 2022-09-30 | 9.59% |
| 2022-06-30 | 9.74% |
| 2022-03-31 | 8.80% |
| 2021-12-31 | 8.13% |
| 2021-09-30 | 5.54% |
| 2021-06-30 | 5.33% |
| 2021-03-31 | 2.13% |
| 2020-12-31 | 4.27% |
| 2020-09-30 | 4.88% |
| 2020-06-30 | 3.13% |
| 2020-03-31 | 4.33% |
| 2019-12-31 | 4.27% |
| 2019-09-30 | 4.64% |
| 2019-06-30 | 27.54% |
| 2019-03-31 | 5.43% |
| 2018-12-31 | 0.73% |
| 2018-09-30 | 0.77% |
| 2018-06-30 | 0.79% |
| 2018-03-31 | 0.80% |
| 2017-12-31 | 0.81% |
| 2017-09-30 | 1.32% |
| 2017-06-30 | 2.10% |
| 2017-03-31 | 3.04% |
| 2016-12-31 | 3.03% |
| 2016-09-30 | 2.67% |
| 2016-06-30 | 3.13% |
| 2016-03-31 | 32.61% |
| 2015-12-31 | 29.54% |
| 2015-09-30 | 36.83% |
| 2015-06-30 | 38.99% |
| 2015-03-31 | 27.91% |
| 2014-12-31 | 24.07% |
| 2014-09-30 | 7.12% |
| 2014-06-30 | 6.35% |
| 2014-03-31 | 4.55% |
| 2013-12-31 | 4.66% |
| 2013-09-30 | 4.15% |
| 2013-06-30 | 3.19% |
| 2013-03-31 | 2.97% |
| 2012-12-31 | 2.50% |
| 2012-09-30 | 2.39% |
| 2012-06-30 | 2.43% |
| 2012-03-31 | 2.09% |
| 2011-12-31 | 3.86% |
| 2011-09-30 | 2.99% |
| 2011-06-30 | 3.38% |
| 2011-03-31 | 3.58% |
| 2010-12-31 | 4.25% |
| 2010-09-30 | 4.20% |
| 2010-06-30 | 4.22% |
| 2010-03-31 | 7.67% |
| 2009-12-31 | 2.08% |
| 2009-09-30 | 2.58% |
| 2009-06-30 | 3.16% |
| 2009-03-31 | 3.42% |
| 2008-12-31 | 3.74% |
| 2008-09-30 | 20.78% |
| 2008-06-30 | 21.31% |
| 2008-02-29 | 0.00% |
| 2007-11-30 | 0.00% |
| 2007-08-31 | 0.00% |
| 2007-05-31 | 0.00% |
| 2007-02-28 | 0.00% |
